Barbara Corcoran, renowned entrepreneur, author, investor and caregiving advocate, is collaborating with Otsuka and Lundbeck LLC to introduce ‘I Wish I Knew,’ a national public education campaign. The campaign is aimed at helping over 11 million family caregivers of people with Alzheimer’s dementia better understand the signs and symptoms of agitation in Alzheimer’s dementia, a separate condition that nearly half of people living with Alzheimer’s dementia show signs of but that many people don’t know exists.

Otsuka Pharmaceutical Co., Ltd. and Jnana Therapeutics Inc. announced that they have entered into a definitive merger agreement pursuant to which Otsuka will acquire Jnana, making it a wholly owned subsidiary through Otsuka's 100-percent owned subsidiary, Otsuka America, Inc. (OAI). The acquisition is expected to be completed in the third quarter of fiscal 2024, subject to customary closing conditions.

Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck Pharmaceuticals LLC presented new post hoc pooled analyses of Phase 3 trials evaluating the safety and efficacy of REXULTI^® (brexpiprazole) in patients with agitation associated with dementia due to Alzheimer’s disease. These data analyses were presented in three posters at the 2024 Alzheimer’s Association International Conference (AAIC), taking place July 28 to Aug. 2 in Philadelphia, USA.

Otsuka Pharmaceutical, Co. Ltd. and H. Lundbeck A/S announce the U.S. Food and Drug Administration (FDA) has determined that the supplemental New Drug Application (sNDA) for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) is sufficiently complete to permit a substantive review. The FDA has assigned the application for a Prescription Drug User Fee Act (PDUFA) target action date of February 8, 2025.

Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck Pharmaceuticals LLC presented results from the Phase II (Trial 061) and Phase III trials (Trial 071 and 072) evaluating the safety and efficacy of brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder. The findings were presented at the American Society of Clinical Psychopharmacology Annual Meeting in Miami.

Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc. announce termination of development of the novel compound AVP-786, which was in development as a potential treatment for patients with agitation associated with dementia due to Alzheimer's disease. 

The School of Global Health at Meharry Medical College (Meharry) with support from Otsuka America Pharmaceutical, Inc., today released The Projected Costs and Economic Impact of Mental Health Inequities in the United States report. Findings show, that if not addressed, mental health inequities combined with expenditures related to chronic conditions, could cost the U.S. economy an estimated $14 trillion between now and 2040.

Otsuka America Pharmaceutical, Inc., announces that the company is the lead, founding sponsor of Caregiving, a two-hour documentary dedicated to portraying the challenges and triumphs of caregivers through their personal stories. The project, executive produced by Bradley Cooper, is slated for release in Spring 2025 and is the next feature film of WETA’s award-winning Well Beings campaign that addresses critical health needs in America.

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S have submitted a supplemental New Drug Application (sNDA) for U.S. Food and Drug Administration (FDA) review of brexpiprazole as combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD) in adults.

Otsuka Pharmaceutical Development & Commercialization, Inc. announces the launch of My Mental Health Journey, a longitudinal registry study that aims to advance research in depression and mental health. Verily Life Sciences LLC (Verily), a precision health technology company, will recruit participants and run the study.